Incyte stock holds firm after strong Q2 2026 earnings

Incyte stock (ISIN US45337C1027) is trading at 126.75 USD as of the Nasdaq close on September 4, 2026, giving the biotechnology group a market capitalization of about 25.69 billion USD according to recent market data.

Q2 2026 results underpin valuation

According to market data compiled by a major stock portal, Incyte reported Q2 fiscal 2026 revenue of 1.67 billion USD and earnings of 585.61 million USD, reflecting a profit margin of 34.98 percent for the quarter.

The same Q2 2026 overview shows that the recent quarterly margin compares favorably with earlier fiscal 2025 quarters, indicating that profitability has improved against historical levels even as the company continues to invest in its pipeline.

Stock performance and peer context

Market data from a capitalization overview show that at a share price of 126.75 USD on September 4, 2026, Incyte stands at a market cap of 25.69 billion USD, while the same source cites a one day share price change of minus 0.98 percent at that close.

The capitalization data also indicate that Incyte has gained 48.35 percent over a recent period, placing the stock performance well ahead of many traditional large cap healthcare names and underlining investor confidence in the company’s revenue and margin trajectory.

Key product and revenue base

Incyte generates a significant portion of its revenue from its dermatology and oncology portfolio, with flagship products such as ruxolitinib based therapies contributing meaningfully to Q2 2026 sales alongside other targeted treatments.

Stock level and investor takeaway

With Incyte stock closing at 126.75 USD on Nasdaq as of September 4, 2026, and supported by Q2 2026 revenue of 1.67 billion USD and a 34.98 percent profit margin, the current valuation near a 25.69 billion USD market capitalization reflects substantial investor expectations for the company’s pipeline and earnings power.